Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers - PubMed (original) (raw)
Comparative Study
. 1993 Sep 14;46(6):1029-36.
doi: 10.1016/0006-2952(93)90667-l.
Affiliations
- PMID: 8216345
- DOI: 10.1016/0006-2952(93)90667-l
Free article
Comparative Study
Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers
C J Koch et al. Biochem Pharmacol. 1993.
Free article
Abstract
Metabolism of misonidazole under hypoxic conditions depletes the parent drug and causes about 4% of the reduced-drug-products to form adducts with cellular macromolecules (binding), and this process has been used to detect hypoxia in cells and tissues. The nitrofuran, AF-2 [2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] has been shown to increase both the metabolic depletion of misonidazole and its binding. In the present study, factors which might affect this process have been examined, in an in vitro system, to test the hypothesis that metabolic depletion of misonidazole could limit its ability to diffuse freely to the hypoxic cell population. Drastic reductions in glucose concentrations from their normal value of 5-10 mM to less than 0.5 mM had no significant effect on the metabolism of either misonidazole or AF-2. Similarly, glucose concentration did not influence the binding of misonidazole, even when concentrations of both oxygen (extreme hypoxia) and glucose were near zero--a very toxic biochemical environment. Similarly, the metabolism of the nitroheterocyclics had no effect on glucose consumption. The bioreductive depletion of misonidazole in extreme hypoxia appeared to be independent of drug concentration between 25 and 100 microM: this nearly zero-order rate of drug metabolism prevented the possibility of working at constant drug concentration. AF-2 exacerbated this effect by greatly enhancing the metabolic depletion of misonidazole. AF-2 was found to increase both the metabolic depletion and binding of misonidazole by the same factor. An unexpected finding was that metabolism of etanidazole, a 2-nitroimidazole closely related to misonidazole, was not enhanced by AF-2. Micromolar amounts of oxygen inhibited the reductive activation of AF-2, and also the interaction between AF-2 and misonidazole. Our results suggest that metabolic depletion of nitroheterocyclics could influence their ability to diffuse adequately to hypoxic tissues, particularly at the low drug concentrations that have been used to measure tissue hypoxia in vivo.
Similar articles
- Enhanced misonidazole binding in the presence of AF-2.
Olive PL. Olive PL. Radiat Res. 1987 Mar;109(3):490-9. Radiat Res. 1987. PMID: 3562787 - Biochemistry of reduction of nitro heterocycles.
Biaglow JE, Varnes ME, Roizen-Towle L, Clark EP, Epp ER, Astor MB, Hall EJ. Biaglow JE, et al. Biochem Pharmacol. 1986 Jan 1;35(1):77-90. doi: 10.1016/0006-2952(86)90561-7. Biochem Pharmacol. 1986. PMID: 2934068 Review. - Comparison between the binding of [3H]misonidazole and AF-2 in Chinese hamster V79 spheroids.
Olive PL, Rasey JS, Durand RE. Olive PL, et al. Radiat Res. 1986 Jan;105(1):105-14. Radiat Res. 1986. PMID: 3945722 - Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration.
Koch CJ, Stobbe CC, Baer KA. Koch CJ, et al. Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1327-31. doi: 10.1016/0360-3016(84)90342-0. Int J Radiat Oncol Biol Phys. 1984. PMID: 6469755 - Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview.
Adams GE, Stratford IJ. Adams GE, et al. Biochem Pharmacol. 1986 Jan 1;35(1):71-6. doi: 10.1016/0006-2952(86)90560-5. Biochem Pharmacol. 1986. PMID: 2934067 Review. No abstract available.
Cited by
- Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide].
Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Evans SM, et al. Br J Cancer. 1995 Oct;72(4):875-82. doi: 10.1038/bjc.1995.427. Br J Cancer. 1995. PMID: 7547234 Free PMC article. - Dosimetry study of 18F-FMISO + PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer.
Li H, Xu D, Han X, Ruan Q, Zhang X, Mi Y, Dong M, Guo S, Lin Y, Wang B, Li G. Li H, et al. Clin Transl Oncol. 2018 Oct;20(10):1329-1336. doi: 10.1007/s12094-018-1864-x. Epub 2018 Apr 5. Clin Transl Oncol. 2018. PMID: 29623584 - Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Evans SM, et al. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1024-31. doi: 10.1016/j.ijrobp.2007.04.067. Int J Radiat Oncol Biol Phys. 2007. PMID: 17967299 Free PMC article. - Hypoxia and VEGF mRNA expression in human tumors.
Ziemer LS, Koch CJ, Maity A, Magarelli DP, Horan AM, Evans SM. Ziemer LS, et al. Neoplasia. 2001 Nov-Dec;3(6):500-8. doi: 10.1038/sj.neo.7900195. Neoplasia. 2001. PMID: 11774032 Free PMC article. Clinical Trial.